Abstract
The Publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) identifies drug products approved by the United States Food and Drug Administration (USFDA) for safety and effectiveness, and provides substantial information on new drug applications (NDAs) with patent data. To explore the patterns among drug patents in the Orange Book, this study used patent bibliometric analysis. The productivity and impact are presented at the assignee level and applicant level, respectively, and the applicant’s patent portfolio is further discussed. 2,033 drug patents are identified in this current study. Our findings indicate that the applicant’s patent portfolio in the Orange Book is helpful in revealing the technological capability and patent strategy of the pharmaceutical incumbents. By linking drug data and patent information, this current study sheds light on patent research in the pharmaceutical industry.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Acosta, M., Coronado, D., & Feranadez, A. (2009). Exploring the quality of environmental technology in Europe: Evidence from patent citations. Scientometrics, 80(1), 131–152.
Bhattacharya, S., & Meyer, M. (2003). Large firms and the science-technology interface: Patents, patent citations, and scientific output of multinational corporations in thin films. Scientometrics, 58(2), 265–279.
Calero, C., Leeuwen, T. N., & Tijssen, R. J. W. (2007). Research cooperation within the bio-pharmaceutical industry: Network analyses of co-publications within and between firms. Scientometrics, 71(1), 87–99.
Ceccagnoli, M., Graham, S. J. H., Higgins, M. J., & Lee, J. (2010). Productivity and the role of complementary assets in form’s demand for technology innovations. Industrial and Corporate Change, 19(3), 839–869.
Chandy, R., Hopstaken, B., Narasimhan, O., & Prabhu, J. (2006). From Invention to innovation: Conversion ability in product development. Journal of Marketing Research, 43(3), 494–508.
Chen, Y. S., & Chang, K. C. (2009). Using neural network to analyze the influence of the patent performance upon the market value of the US pharmaceutical companies. Scientometrics, 80(3), 637–655.
Chen, Y. S., & Chang, K. C. (2010a). Analyzing the nonlinear effects of firm size, profitability, and employee productivity on patent citations of the US pharmaceutical companies by using citations of the US pharmaceutical companies by using artificial neural network. Scientometrics, 82(1), 75–82.
Chen, Y. S., & Chang, K. C. (2010b). The nonlinear nature of the relationships between the patent traits and corporate performance. Scientometrics, 82(1), 201–210.
Chen, D. Z., Huang, H. W., Huang, M. H., & Fu, F. C. (2005). Core technologies and key industries in Taiwan from 1978 to 2002: A perspective from patent analysis. Scientometrics, 64(1), 31–53.
Cohen, W. M., & Levinthal, D. A. (1990). Absorptive capability: A new perspective on learning innovation. Administration Science Quarterly, 35(1), 128–152.
Dimasi, J. A. (2001). Risks in new drug development: Approval success rates for investigational drugs, Clinical Pharmacology and Therapeutics, 29(May), 297–307.
Dominguez-Lacasa, I. (2006). Capturing the changes in the knowledge base underlying drug discovery and development in the 20th century and the adjustment of Bayer, Hoechst, Schering AG and E. Merck to the advent of modern biotechnology. Scientometrics, 66(2), 345–364.
Hall, B. H., Jaffe, A., & Trajtenberg, M. (2005). Market value and patent citations. Rand Journal of Economics, 36(1), 16–38.
Hill, L. L. (2005). Patent primer, The Orange Book. Nature Reviews Drug Discovery, 4(8), 261.
Iversen, E. J. (2000). An excursion into the patent-bibliometrics of Norwegian patenting. Scientometrics, 49(1), 63–80.
Koenig, M. E. D., & Mezick, E. M. (2004). Impact of mergers and acquisitions on research productivity within the pharmaceutical industry. Scientometrics, 59(1), 157–169.
Lo, S. C. (2007). Patent analysis of genetic engineering research in Japan, Korea and Taiwan. Scientometrics, 70(1), 183–200.
Lo, S. C. (2008). Patent coupling analysis of primary organizations in genetic engineering research. Scientometrics, 74(1), 143–151.
Mcmillan, G. S., & Hamilton, R. D. (2000). Using Bibliometrics to measure firm knowledge: An analysis of the US pharmaceutical industry. Technology Analysis and Strategic Management, 12(4), 465–475.
Mcmillan, G. S., & Hamilton, R. D. (2007). The public science base of US biotechnology: A citation-weighted approach. Scientometrics, 72(1), 3–10.
Narin, F. (1994). Patent bibliometrics. Scientometrics, 30(1), 147–155.
USFDA (2010) Approved drug products with therapeutic equivalence evaluations. 30th edn. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf. Accessed 19 April 2010.
Van Looy, B., Magerman, T., & Debbakere, K. (2007). Developing technology in the vicinity of science: An examination of the relationship between science intensity (of patents) and technological productivity within the field of biotechnology. Scientometrics, 70(2), 441–458.
Wang, M. H., Yu, T. C., & Ho, Y. S. (2010). A bibliometrics analysis of the performance of water research. Scientometrics, 84(3), 813–820.
Yang, S., Ma, F., Song, Y., & Qiu, J. (2010). A longitudinal analysis of citation distribution breadth for Chinese scholars. Scientometrics, 85(3), 755–765.
Yuan, J. P., Yue, W. P., Su, C., Wu, Z., Ma, Z., Pan, Y. T., et al. (2010). Patent activity on water pollution and treatment in China- a scientometric perspective. Scientometrics, 83(3), 639–651.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, MC., Fang, SC. & Chang, SC. Tracking R&D behavior: bibliometric analysis of drug patents in the Orange Book. Scientometrics 88, 805–818 (2011). https://doi.org/10.1007/s11192-011-0400-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11192-011-0400-3